You are here

DYNAVAX TECHNOLOGIES CORPORATION

Company Information
Address
2929 7TH ST STE 100
BERKELEY, CA 94710-2753
United States


http://www.dynavax.com

Information

UEI: JA7GSG397PL1

# of Employees: 156


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Developing small molecule inhibitors of TLR for treatment of rheumatoid arthritis

    Amount: $1,012,267.00

    DESCRIPTION provided by applicant Autoimmune diseases like rheumatoid arthritis RA develop when the immune response targets self antigens leading to inflammation and tissue destruction There i ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  2. The Development of TLR Antagonists for Therapy of Hepatic Fibrosis and Cirrhosis

    Amount: $223,390.00

    DESCRIPTION (provided by applicant): Hepatic fibrosis (HF) is a major health problem leading to cirrhosis and death. There is currently no pharmacological treatment for HF, and liver transplantation ...

    STTRPhase I2013Department of Health and Human Services National Institutes of Health
  3. Development of TLR8 inhibitors for treatment of autoimmune diseases

    Amount: $599,016.00

    DESCRIPTION (provided by applicant): Autoimmune diseases develop when the adaptive immune response targets self-antigens, leading to inflammation and tissue destruction. The innate immune system faces ...

    SBIRPhase I2012Department of Health and Human Services National Institutes of Health
  4. Screening for Inhibitors of TLR8 for Treatment of Rheumatoid Arthritis

    Amount: $404,918.00

    DESCRIPTION (provided by applicant): Autoimmune diseases develop when the adaptive immune response targets self-antigens, leading to inflammation and tissue destruction. The innate immune system faces ...

    SBIRPhase I2012Department of Health and Human Services National Institutes of Health
  5. Inhibitors of PI3K-delta for Treatment of Skin Inflammation

    Amount: $595,550.00

    DESCRIPTION (provided by applicant): Systemic lupus erythematosus (SLE) is an autoimmune disease that affects over a million people in the United States, disproportionately affecting women of chil ...

    SBIRPhase I2011Department of Health and Human Services National Institutes of Health
  6. Development of an L2-based HPV vaccine to generate broad immunity

    Amount: $595,825.00

    DESCRIPTION (provided by applicant): Cervical cancer accounts for nearly 10% of all cancers in women and is the second leading cause of death from cancer in women worldwide. More than 470,000 cases a ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  7. Inhibitors of Toll-like receptors 7 and 9 for treatment of skin inflammation

    Amount: $720,339.00

    DESCRIPTION (provided by applicant): Lupus is an autoimmune disease that affects over a million people in the United States, disproportionately affecting women of childbearing age. It is difficult to ...

    SBIRPhase I2009Department of Health and Human Services National Institutes of Health
  8. Development of an inhibitory oligonucleotide for the treatment of lupus

    Amount: $1,811,030.00

    DESCRIPTION (provided by applicant): Project summary/Abstract Systemic lupus erythematosus (lupus) is an autoimmune disease that affects over a million people in the United States, disproportionately ...

    SBIRPhase II2008Department of Health and Human Services National Institutes of Health
  9. Development of an Inhibitory Oligonucleotide for the Treatment of Lupus

    Amount: $207,278.00

    DESCRIPTION (provided by applicant): Systemic lupus erythematosis (SLE) is a complex autoimmune disease that affects multiple organ systems and affects preferentially young to middle-aged women. It ha ...

    SBIRPhase I2006Department of Health and Human Services National Institutes of Health
  10. INDUCTION OF ANTI-HPV CTL WITH PEPTIDE-CPG DNA CONJUGATE

    Amount: $119,349.00

    DESCRIPTION (provided by applicant): The goal of this research program is to produce peptide-immunostimulatory (ISS) DNA conjugates that can stimulate robust anti-papillomavirus Th1 and CTL responses. ...

    SBIRPhase I2002Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government